Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04545450
Other study ID # DUTMUSCLE-20
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 4, 2008
Est. completion date October 15, 2010

Study information

Verified date September 2020
Source Unita Complessa di Ostetricia e Ginecologia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the effects on body composition and muscle strengthof 54-weeks treatment with of testosterone undecanoate combined with placebo or with the 5a-reductase inhibitor dutasteride


Description:

Transmen who have undergone gender-affirming surgery require long-lasting treatments with androgens to maintain male phenotypic characteristics and to preserve their health. In this population the effects on muscle and the relative role of testosterone and its metabolite dihydrotestosterone (DHT) on the skeletal muscle are still largely unknown.

In this pilot study, we evaluated the effects of testosterone and DHT on muscle strength, body composition, metabolism. Also cutaneous androgenic effects such as acne and androgenetic alopecia were evaluated.

DESIGN

For this purpose, in this randomized, double-blind placebo-controlled pilot trial we treated variectomized transmen for 54 weeks with:

- Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill (TU+PL)

- TU 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day (TU+DUT).

Prospective, phase III, randomized study design was used.

Subjects were seen every 12 weeks for safety monitoring that included evaluation of hematocrit, transaminases, alkaline phosphatases and bilirubin, creatinine, urea and serum electrolyte as potassium and sodium.

Baseline and week-54 evaluations included the following measurements:

blood drawings for measurements of: hormonal profile (serum testosterone, estradiol, luteinizing hormone and follicle-stimulating hormone, prolactin, sex hormone binding globulin, and thyroid stimulating hormone), haematocrit (Ht) and haemoglobin (Hb), glucidic and lipidic profile (fasting glucose, fasting insulin, total cholesterol, high- and low-density lipoproteins, and triglycerides), hepatic function (aspartate and alanine aminotransferases) and bone related markers (osteocalcin, parathyroid hormone, bone alkaline phosphatase and 25-hydroxyvitamin, 24h urinary excretion of calcium, potassium, magnesium and creatinine).

anthropometry: weight, measures DEXA for bone mass determination and body composition Isokinetic knee extension and flexion peak torque (PT-IKE and PT-IKF) Handgrip strength evalutation of the psychological profile with the brief Profile of Mood State (POMS) sexual life satisfaction evalutation with a Visual Analogue General Satisfaction Scale (VAS) physical examination: inspection of external genitalia (clitorides) and a visit to detect appearance of acne and gynecomastia

During the treatment phase all injections will be administered by the investigator or co-investigators for the entire study. Fasting (10 hours) blood samples will be taken (immediately before giving the injections) every time subjects come for injections (week 0, 6, 18, 30 and 42) and at the end of the treatment phase.

In the sexual and behavior questionnaire the subjects will judge their sexual activity and behavior in the period between visits. The subjects have the possibility to making additional comments about important events and disturbances.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date October 15, 2010
Est. primary completion date July 30, 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy transmen

- Previous bilateral gonadectomy during sex reassigning surgery

- Body Mass Index (BMI) between 20 and 29 kg/m²; (body weight in kilograms divided by body height in meters squared)

- Clinical examination without pathological findings relevant to the study

- No concomitant use of drugs known to affect the hypothalamic-pituitary-ovarian axis

- Written Consent Form

- High probability of a good compliance and termination of the study

Exclusion Criteria:

- Participation in another clinical trial within the 30 days preceding the first administration

- Simultaneous participation in another clinical trial

- Subjects institutionalized or imprisoned by order of the court

- Subject who compete in sports

- Subjects reporting desire to perform regular physical exercises for the duration of the study

- Serious organic or psychic disease suspected from history and/or clinical examination

- Diseases (especially tumors) that might represent an actual contraindication for testosterone

- Past or present history of thrombotic or embolic diseases

- Arterial hypertension

- Diabetes mellitus

- Acute or chronic hepatic diseases

- Manifest renal diseases with renal dysfunction

- Severe internal diseases

- Biochemical and/or hematological laboratory values beyond normal ranges unless the Investigator confirms that the deviations are of no clinical relevance

- Any indication of chronic use of drugs, alcohol, opiates or recreational drugs

- Use of any drug known to affect biotransformation of testosterone and/or progestin, e.g. chlorcycline, phenobarbital, phenylbutazone, aminophenazone within the 30 days preceding the first administration of the test medication and during the study

- Use of oral anticoagulatory drugs within the 30 days preceding the first administration of the test medication and during the study

- Any oral or transdermal hormone medication within the 12 weeks preceding the first administration and during the study

- Probability of poor compliance and termination of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dutasteride 5 mg/day
Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
Testosterone Undecanoate
Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Unita Complessa di Ostetricia e Ginecologia

Outcome

Type Measure Description Time frame Safety issue
Primary Change in isokinetic knee extension and flexion peak torque (PT-IKE and PT-IKF) Isokinetic peak torques were determined using isokinetic dynamometry (Biodex System 4 Pro, Medical Systems, Shirley, NY) at all four time points. At baseline and after 54 weeks of treatment
Primary Change in handgrip strength Three trials of three sets of maximal isometric handgrip on a mechanical dynamometer (model Grip-A, Takei Physical Fitness Test TKK 5001, Japan), alternately with the dominant and non-dominant hand, with a three minute rest between each trial At baseline and after 54 weeks of treatment
Primary Change in body composition Dual-energy X-ray absorptiometry was performed using the Hologic 49159 densitometer and standard QDR body composition software (Model QDR4500W, Software Level 11.2, Hologic Spine; Hologic, Bedford, MA) for the measurement of body fat and lean mass At baseline and after 54 weeks of treatment
Primary Change in bone mineral density Dual-energy X-ray absorptiometry was performed using the Hologic 49159 densitometer and standard QDR body composition software (Model QDR4500W, Software Level 11.2, Hologic Spine; Hologic, Bedford, MA) for the evaluation of bone mineral density at lumbar and femoral site At baseline and after 54 weeks of treatment
Primary Change in anthropometric assessment: BMI weight, stature will be combined to report the BMI (kg/m^2) At baseline and after 54 weeks of treatment
Primary Change in anthropometric assessment: waist-to-hip ratio Waist and hip circumferences will be combined to report the waist-to-hip ratio (WHR) At baseline and after 54 weeks of treatment
Secondary Change in psychological profile with the brief Profile of Mood State (POMS) The POMS is a self-reporting questionnaire consisting of 30 items in six categories: tension-anxiety, depression, anger-hostility, vigor, fatigue and confusion, which are scored from 1-4 according to severity At baseline and after 54 weeks of treatment
Secondary Change in the satisfaction with their sexual life using a Visual Analogue General Satisfaction Scale (VAS). A VAS for satisfaction is a horizontal line of 10-cm long. At the start and finish there are two descriptors representing extremes of satisfaction (i.e. no satisfaction and extreme satisfaction). Subjects respond to the question 'Are you satisfied with your sexual life now?' and rate their satisfaction by making a vertical mark on the 100-mm line. The measurement in millimeters is converted to the same number of points ranging from zero to 10 points. At baseline and after 54 weeks of treatment
Secondary Change in in the bone metabolism: osteocalcin Evaluation of serum osteocalcin (OC) change At baseline and after 54 weeks of treatment
Secondary Change in in the bone metabolism: parathyroid hormone Evaluation of serum parathyroid hormone (PTH) changes At baseline and after 54 weeks of treatment
Secondary Change in in the bone metabolism: bone alkaline phosphatase Evaluation of serum bone alkaline phosphatase (BAP) changes At baseline and after 54 weeks of treatment
Secondary Change in in the bone metabolism: urinary excretion of electrolites Changes in the 24h urinary excretion of electrolites At baseline and after 54 weeks of treatment
Secondary Change in in the insulin resistance Change in the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) At baseline and after 54 weeks of treatment
Secondary Change in the lipid profile Changes in cholesterol (Tot Chol and high- and low-density lipoproteins) levels At baseline and after 54 weeks of treatment
Secondary Change in the lipid profile Changes in triglycerides levels At baseline and after 54 weeks of treatment
See also
  Status Clinical Trial Phase
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Terminated NCT02419105 - Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors Phase 3
Withdrawn NCT02137265 - Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism N/A
Completed NCT02233751 - Pharmacokinetic Study of Subcutaneous Testosterone Enanthate Phase 1
Completed NCT02222558 - Oral Testosterone for the Treatment of Hypogonadism in Males Phase 2
Completed NCT01887418 - Pharmacokinetic Study of Testosterone Enanthate Phase 1/Phase 2
Terminated NCT01092858 - NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) Phase 4
Completed NCT00624624 - Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism N/A
Completed NCT00752869 - Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Phase 4
Completed NCT00613288 - Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism N/A
Completed NCT00838838 - Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis N/A
Completed NCT00119483 - Older Men and Testosterone N/A
Completed NCT00004438 - Leuprolide in Treating Adults With Hypogonadotropism N/A
Withdrawn NCT00398034 - Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study. Phase 2
Completed NCT02937740 - Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Phase 4
Completed NCT02921386 - The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Phase 2
Completed NCT01717768 - Oral Testosterone for the Treatment of Hypogonadism Phase 2
Terminated NCT01460654 - Testosterone and Alendronate in Hypogonadal Men Phase 2
Completed NCT00998933 - Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure Phase 1
Withdrawn NCT00710827 - Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks Phase 4